Drug Profile
Yinlitinib - HEC Pharm
Alternative Names: Yinlitinib maleateLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Solid-tumours in China
- 22 May 2019 Phase-I clinical trials in Solid tumours in China (unspecified route) (HEC Pharm pipeline, May 2019)
- 25 Aug 2015 Preclinical trials in Solid tumours in China (unspecified route) prior to August 2016 (HEC Pharma pipeline, August 2016)